A phase 2 study of nivolumab combined with daratumumab with or without lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Trial Profile

A phase 2 study of nivolumab combined with daratumumab with or without lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Nivolumab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms NIVO/DARA study
  • Most Recent Events

    • 05 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top